Roche Holding AG (RHHBY)

Market Cap	262.87B
Revenue	68.39B
Net Income	13.98B
Shares Out	6.45B
EPS	2.01
PE Ratio	20.02
Forward PE	12.72
Dividend	$1.39 (3.42%)
Ex-Dividend Date	Mar 14, 2024

Volume	494,124
Open	39.35
Previous Close	39.65
Day's Range	n/a
52-Week Range	29.20 - 40.80
Beta	0.13
Analysts	Hold
Price Target	40.00 (-1.89%)
Earnings Date	n/a

About RHHBY

Roche Holding AG engages in the pharmaceuticals and diagnostics businesses in Europe, North America, Latin America, Asia, Africa, Australia, and Oceania. The company offers pharmaceutical products in the therapeutic areas of anemia, blood and solid tumors, dermatology, hemophilia, inflammatory and autoimmune, neurological disorders, ophthalmology, respiratory disorders, and transplantation. It is also developing products for various therapeutic areas. In addition, it offers in vitro tests for the diagnosis of various diseases, such as cancer, d...

• Industry: Drug Manufacturers - General
• Sector: Healthcare
• Founded: 1896
• Employees: 103,605
• Stock Exchange: OTCMKTS
• Ticker Symbol: RHHBY

Financial Performance

In 2023, RHHBY's revenue was 60.44 billion, a decrease of -8.16% compared to the previous year's 65.81 billion. Earnings were 11.50 billion, a decrease of -7.43%.

Financial numbers in CHF

Analyst Forecast

According to one analyst, the rating for RHHBY stock is "Hold" and the 12-month stock price forecast is $40.0.

Price Target

$40.0

(-1.89% downside)

Analyst Consensus: Hold